Skip to main
DMAAU
DMAAU logo

DMAAU Market Capitalization Overview

Market Cap: $107.61M as of Jun 13, 2025

$107.61M
Past Month+$418.30K (0.39%)
As of Jun 13, 2025, DMAAU has a market capitalization of $107.61M. Over the past 30 days, its market cap has increased by 3.04%, while in the last 12 months, it has increased by .

Market capitalization represents the total value of Drugs Made In America Acquisition Corp as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

DMAAU Market Cap Formula = Stock Price * Shares Outstanding

The market cap of DMAAU helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

DMAAU Market Cap History

DateMarket CapChange
Jun 2, 2025$109.80M+3.04%
May 1, 2025$106.56M+0.69%
Apr 1, 2025$105.83M-0.78%
Mar 3, 2025$106.67M-63.51%
Feb 3, 2025$292.30M+0.20%
Jan 27, 2025$291.72M

DMAAU End of Year Market Cap History

DateMarket CapChange
2025$107.61M

FAQs About Drugs Made In America Acquisition Corp (DMAAU) Market Cap

As of Jun 13, 2025, the market capitalization of DMAAU is $107.61M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Drugs Made In America Acquisition Corp’s market capitalization has increased by 0.3900%, changing from $107.19M to $107.61M as of Jun 13, 2025.

In the last 3 months, Drugs Made In America Acquisition Corp’s market capitalization has increased by —, changing from – to – as of –.

In the year –, Drugs Made In America Acquisition Corp’s market capitalization increased from – in January to – in December, reflecting a — change.

Drugs Made In America Acquisition Corp (DMAAU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.